Ignite Creation Date:
2024-05-05 @ 12:02 PM
Last Modification Date:
2024-10-26 @ 9:18 AM
Study NCT ID:
NCT00212888
Status:
COMPLETED
Last Update Posted:
2019-06-17
First Post:
2005-09-13
Brief Title:
Combination Vaccination Before HIV Treatment Interruption
Sponsor:
Ottawa Hospital Research Institute
Organization:
Ottawa Hospital Research Institute
Study Overview
Official Title:
A Pilot Study to Determine the Impact of Therapeutic HIV Vaccination Followed by a Scheduled Interruption of Antiretroviral Therapy on HIV-Specific Immune Function and Virologic Rebound in Patients With Prolonged Viral Suppression
Status:
COMPLETED
Status Verified Date:
2019-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to determine if vaccination before a structured treatment interruption STI is associated with an improvement in immune function resulting in a delayed and reduced rebound in the amount of HIV virus in the blood
Detailed Description:
Volunteers will be randomly assigned to receive the vaccines or matching placebos before interrupting their antiretroviral therapy at week 24
Dosage
RemuneTM 1 ml im at weeks 0 12 and 20 ALVAC 1 ml im at weeks 812 16 and 20
im injected in a muscle
Dosage
RemuneTM 1 ml im at weeks 0 12 and 20 ALVAC 1 ml im at weeks 812 16 and 20
im injected in a muscle
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| CTA file 9427-C1574-32C | None | None | None |